ATARA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

A securities class action lawsuit has been filed against Atara Biotherapeutics for allegedly making false and misleading statements regarding manufacturing issues and deficiencies in the ALLELE study that undermined FDA approval prospects for tabelecleucel. Investors who purchased securities between May 20, 2024 and January 9, 2026 may be eligible for compensation. The lead plaintiff deadline is May 22, 2026.

05/19/2026, 6:22 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Atara Biotherapeutics, Inc. alleging that company executives made false and misleading statements regarding manufacturing issues and deficiencies in the ALLELE study that would likely prevent FDA approval of tabelecleucel. The lawsuit covers investors who purchased Atara securities between May 20, 2024 and January 9, 2026.

05/18/2026, 12:00 PM • GlobeNewswire

DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Atara Biotherapeutics (ATRA), Coty Inc. (COTY), Super Micro Computer (SMCI), and ImmunityBio (IBRX). The lawsuits allege that defendants made false or misleading statements regarding their business operations and prospects. Lead plaintiff deadlines range from May 22-26, 2026.

05/14/2026, 2:45 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Atara Biotherapeutics, Inc. alleging that company executives made false and misleading statements regarding manufacturing issues and deficiencies in the ALLELE study that would likely prevent FDA approval of tabelecleucel. The lawsuit covers investors who purchased Atara securities between May 20, 2024 and January 9, 2026. The lead plaintiff deadline is May 22, 2026.

05/14/2026, 12:00 PM • GlobeNewswire

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors to join a class action lawsuit against Atara Biotherapeutics for alleged securities fraud. The company allegedly made false and misleading statements regarding manufacturing problems and deficiencies in its ALLELE study for tabelecleucel, overstating the drug's prospects and concealing regulatory risks. Investors who purchased securities between May 20, 2024 and January 9, 2026 are encouraged to participate.

05/13/2026, 10:34 PM • GlobeNewswire

Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Atara Biotherapeutics faces a class action securities fraud lawsuit after the FDA rejected its Epstein-Barr virus treatment (tabelecleucel/EBVALLO) twice due to manufacturing issues and inadequate trial design. The stock plummeted 40.5% on January 16, 2025, and another 57% on January 12, 2026, following the rejections. Shareholders who purchased ATRA securities between May 20, 2024 and January 9, 2026 are urged to file lead plaintiff motions by May 22, 2026.

05/12/2026, 2:00 PM • GlobeNewswire

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

Rosen Law Firm is soliciting investors in Atara Biotherapeutics who purchased securities between May 20, 2024 and January 9, 2026 to join a class action lawsuit. The lawsuit alleges that Atara made false statements regarding manufacturing issues and deficiencies in the ALLELE study that made FDA approval of tabelecleucel unlikely, and that regulatory prospects were overstated. The lead plaintiff deadline is May 22, 2026.

05/11/2026, 7:53 PM • GlobeNewswire

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Graphic Packaging Holding Company Investors to Secure Counsel Before Important Deadline in Securities Class Action – GPK

Rosen Law Firm has filed class action lawsuits on behalf of investors in Graphic Packaging Holding Company and other firms. The lawsuit alleges that Graphic Packaging made false statements regarding inventory management, demand, costs, and financial guidance during the Class Period (February 4, 2025 - February 2, 2026). Investors who purchased securities during this period may be eligible for compensation. The deadline to serve as lead plaintiff is July 6, 2026.

05/11/2026, 7:37 PM • GlobeNewswire

Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your Rights – ATRA

Levi & Korsinsky announces a class action securities lawsuit against Atara Biotherapeutics for alleged fraud between May 20, 2024 and January 9, 2026. The complaint alleges the company made false statements about manufacturing issues and deficiencies in the ALLELE study that made FDA approval of tabelecleucel unlikely, while overstating regulatory prospects. Investors who suffered losses during this period can request lead plaintiff status by May 22, 2026.

05/11/2026, 4:00 PM • GlobeNewswire

UPST Investor Alert: Upstart Holdings Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Inflated AI Projections: Levi & Korsinsky

Upstart Holdings faces a securities class action lawsuit after allegedly inflating AI model performance projections. The company's flagship AI underwriting model suppressed loan approvals in Q3 2025, leading to a $4.49 per share (9.71%) decline and a $44 million revenue guidance cut. Institutional investors who purchased shares between May 14, 2025 and November 4, 2025 may seek lead plaintiff status by June 8, 2026.

05/11/2026, 4:00 PM • GlobeNewswire

DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Atara Biotherapeutics, Coty Inc., Super Micro Computer, and ImmunityBio. The lawsuits allege that defendants made false or misleading statements regarding their business operations and prospects. Investors have until late May 2026 to file lead plaintiff motions.

05/07/2026, 1:54 PM • GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit

A class action lawsuit has been filed against Atara Biotherapeutics for allegedly issuing false and misleading statements regarding manufacturing issues and deficiencies in the ALLELE study that made FDA approval of tabelecleucel unlikely. The lawsuit covers securities purchased between May 20, 2024 and January 9, 2026, with investors having until May 22, 2026 to apply as lead plaintiff.

05/05/2026, 6:23 PM • GlobeNewswire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

Rosen Law Firm is reminding investors who purchased Atara Biotherapeutics securities between May 20, 2024 and January 9, 2026 of the May 22, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Atara made false statements regarding manufacturing issues and deficiencies in the ALLELE study that made FDA approval of tabelecleucel unlikely, while overstating the drug's regulatory prospects.

05/02/2026, 3:30 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Atara Biotherapeutics alleging securities fraud. The complaint claims the company made false statements about manufacturing issues and deficiencies in the ALLELE study that would likely prevent FDA approval of tabelecleucel. Investors who purchased Atara securities between May 20, 2024 and January 9, 2026 may be eligible to join the case.

04/30/2026, 12:00 PM • GlobeNewswire

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA

Pomerantz LLP filed a class action lawsuit against Atara Biotherapeutics (NASDAQ: ATRA) for alleged securities fraud. The lawsuit covers investors who purchased Atara securities between May 20, 2024 and January 9, 2026. Defendants allegedly made false statements about tabelecleucel's regulatory prospects, concealing manufacturing issues and study deficiencies. The FDA issued Complete Response Letters rejecting the drug's approval application, causing significant stock price declines of 40.5%, 7.91%, and 56.99% on three separate dates in January 2025 and 2026.

04/28/2026, 3:46 PM • GlobeNewswire